Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
D004066 | Digestive System Diseases NIH | 0.58 |
D005767 | Gastrointestinal Diseases NIH | 0.58 |
D003141 | Communicable Diseases NIH | 0.07 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0011024 | Abnormality of the gastrointestinal tract HPO | 0.41 |
Navigate: Correlations HPO
There is one clinical trial.
Corona virus Disease 2019 (COVID-19) can be a severe respiratory illness caused by Severe Acute Respiratory Syndrome (SARS-CoV2) for which there is no standard treatment in affected persons nor a vaccine to prevent the infection. The investigators propose to test whether the use of Convalescent plasma given to patients with severe COVID-19 disease will decrease risk of death, decrease use of ventilatory support decrease biomarkers of inflammation and improve measures of viral replication compared with controls subjects who were not transfused.Convalescent plasma, will be collected from persons who are more than 21 days post negative viral testing or 28 days post resolution of symptoms.
Description: Number of deaths
Measure: Mortality Time: Time from Admission up 28 days post-dischargeDescription: COVID-19 Viral titres
Measure: Viral load Time: Change in viral titres up to 28 days after transfusion measured on day 1, 3, 5, 7, 14, 28 after receiving transfusionDescription: Antibody titre for IgG anti-SARS-CoV-2 antibody
Measure: Antibody titre for Immunoglobulin (IgG) anti-SARS-CoV-2 antibody Time: Change in antibody titres up to 28 days after transfusion measured on day 1, 3, 5, 7, 14, 28 after receiving transfusionDescription: Antibody titre for IgA anti-SARS-CoV-2 antibody
Measure: Antibody titre for Immunoglobulin A (IgA) anti-SARS-CoV-2 antibody Time: Change in antibody titres up to 28 days after transfusion measured on day 1, 3, 5, 7, 14, 28 after receiving transfusionDescription: Procalcitonin levels
Measure: Procalcitonin titres Time: Change in titres up to 28 days after transfusion measured on day 1, 3, 5, 7, 14, 28 after receiving transfusionDescription: Interleukin 6 (IL-6) levels
Measure: Interleukin 6 (IL-6) Time: Change in titres up to 28 days after transfusion measured on day 1, 3, 5, 7, 14, 28 after receiving transfusionDescription: D-dimer levels
Measure: D-dimer Time: Change in titres up to 28 days after transfusion measured on day 1, 3, 5, 7, 14, 28 after receiving transfusionDescription: C- reactive protein levels
Measure: C-reactive protein Time: Change in titres up to 28 days after transfusion measured on day 1, 3, 5, 7, 14, 28 after receiving transfusionDescription: Ferritin levels
Measure: Ferritin Time: Change in titres up to 28 days after transfusion measured on day 1, 3, 5, 7, 14, 28 after receiving transfusionDescription: Duration of stay in ICU
Measure: Length of ICU admission Time: Number of days from hospital admission up to day of discharge assessed up to 100 daysDescription: Time to recovery
Measure: Days to recovery Time: Number of days from hospital admission up to the day of recovery assessed up to 100 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports